128 related articles for article (PubMed ID: 34938624)
1. Real World Utilization of Bamlanivimab at a Rural Community Hospital.
Leavitt R; Ash J; Hasenbalg P; Santarelli A; Dietrich T; Schritter S; Wells J; Dawson A; Ashurst J
Cureus; 2021 Nov; 13(11):e19747. PubMed ID: 34938624
[TBL] [Abstract][Full Text] [Related]
2. Real world utilization of REGEN-COV2 at a community hospital.
Ash J; Leavitt R; Dietrich T; Schritter S; Wells J; Santarelli A; Ashurst J
Am J Emerg Med; 2021 Dec; 50():129-131. PubMed ID: 34364110
[TBL] [Abstract][Full Text] [Related]
3. Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals.
Quenzer FC; Lafree AT; Grey L; Singh S; Smyers C; Balog B; Guedez HM; McIntyre K; Wulfovich S; Ramirez J; Saikhon T; Tomaszewski C
West J Emerg Med; 2022 Mar; 23(3):302-311. PubMed ID: 35679495
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community.
Iqbal L; Terlau TJ; Hernandez A; Woods K
Cureus; 2021 Jul; 13(7):e16477. PubMed ID: 34430093
[TBL] [Abstract][Full Text] [Related]
5. Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients.
Pham DH; Wong S; Nguyen CT; Lee SC; Won KJ
Healthcare (Basel); 2021 Dec; 10(1):. PubMed ID: 35052205
[TBL] [Abstract][Full Text] [Related]
6. Bamlanivimab Use in a Military Treatment Facility.
Karr E; Chung T; Burtson K; Markert R; Kelly D
Mil Med; 2022 Oct; 187(11-12):e1261-e1264. PubMed ID: 33993281
[TBL] [Abstract][Full Text] [Related]
7. A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019.
Abbas M; Farhat N; Hammoud Z; Dickey C; Shuayto A; Chen NW; Hsaiky LM; Sims M; Sengstock D; Schramski J; Shamoon Z
J Intensive Care Med; 2023 Jun; 38(6):511-518. PubMed ID: 36775970
[No Abstract] [Full Text] [Related]
8. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
9. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
[TBL] [Abstract][Full Text] [Related]
11. Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19.
Melton JD; Wilson K; Blind F; Barbera A; Bhisitkul D; Hasara S; Homa K; Karp J; Escowitz H; Haber T; DeGroot D; Anderson J; DeLeon J; Santos JL; Faviere D; Fuell J; Gillespie R; Glueck J; Reeber C; Rhodes DJ; Rodriguez V
Am J Emerg Med; 2021 Dec; 50():437-441. PubMed ID: 34487951
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
[TBL] [Abstract][Full Text] [Related]
13. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Bariola JR; McCreary EK; Wadas RJ; Kip KE; Marroquin OC; Minnier T; Koscumb S; Collins K; Schmidhofer M; Shovel JA; Wisniewski MK; Sullivan C; Yealy DM; Nace DA; Huang DT; Haidar G; Khadem T; Linstrum K; Seymour CW; Montgomery SK; Angus DC; Snyder GM
Open Forum Infect Dis; 2021 Jul; 8(7):ofab254. PubMed ID: 34250192
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients.
Milam AN; Doan DT; Childress DT; Durham SH
J Pharm Technol; 2022 Jun; 38(3):169-173. PubMed ID: 35600282
[TBL] [Abstract][Full Text] [Related]
15. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
Destache CJ; Aurit SJ; Schmidt D; Peet Erkes L; Tierney M; Vivekanandan R
Pharmacotherapy; 2021 Sep; 41(9):743-747. PubMed ID: 34328670
[TBL] [Abstract][Full Text] [Related]
16. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Ganesh R; Pawlowski CF; O'Horo JC; Arndt LL; Arndt RF; Bell SJ; Bierle DM; Borgen MD; Hanson SN; Heyliger A; Larsen JJ; Lenehan PJ; Orenstein R; Puranik A; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Razonable RR
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34411003
[TBL] [Abstract][Full Text] [Related]
17. Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19.
Ganesh R; Pawlowski C; O'Horo JC; Arndt LL; Arndt R; Bell SJ; Bierle DM; Borgen MD; Hanson SN; Heyliger A; Larsen JJ; Lenehan P; Orenstein R; Puranik A; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Razonable RR
medRxiv; 2021 May; ():. PubMed ID: 34075387
[TBL] [Abstract][Full Text] [Related]
18. Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities.
Walker VL; Meyer A; Paauw D; Arend M
J Am Med Dir Assoc; 2022 Jan; 23(1):141-145. PubMed ID: 34890559
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting.
Corwin DS; Ender PT; Sahu N; Durgham RA; McGorry DM; Rahman A; Stoltzfus J; Jahre JA
Open Forum Infect Dis; 2021 Jul; 8(7):ofab305. PubMed ID: 34258324
[TBL] [Abstract][Full Text] [Related]
20. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG
Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
